Abstracts

WS01.03Factors associated with persistent Pseudomonas aeruginosa infection following elexacaftor/tezacaftor/ivacaftor treatment: insights from the European Cystic Fibrosis Society Patient Registry. Journal of Cystic Fibrosis, 24, S2.

Pollak, M., Gambazza, S., Orenti, A., de Rose, V., Prais, D., Kerem, E., & Mei-Zahav, M. (2025).

EPS2.10Transitioning to race-neutral reference equations on lung function for people with cystic fibrosis: which consequences for Europe? Journal of Cystic Fibrosis, 24, S45.

Zolin, A., Gambazza, S., Burgel, P.-R., Carr, S., Lammertyn, E., Lindblad, A., Macek, M., Bakkeheim, E., & Naehrlich, L. (2025).

P363 Changes in prescription of inhaled antibiotics between 2012-2019 in the European Cystic Fibrosis Patient Registry. Journal of Cystic Fibrosis, 24, S181–S182.

Muhlebach, M. S., Carr, S., Naehrlich, L., Orenti, A., & Gambazza, S. (2025).

Incidence, Prevalence and Patterns of Stenotrophomonas Maltophilia Infection in People with Cystic Fibrosis across Europe. Società Italiana di Statistica Medica ed Epidemiologia Clinica (SISMEC) XIII Congresso - Pavia (Italy). Settembre 2025. Epidemiology, Biostatistics, and Public Health. 

Zanzi, R., Orenti, A., Zolin, A., Mei-Zahav, M., Prais, D., & Gambazza, S.

Evaluating The Real-World Effectiveness Of A New Class Of Drugs For Cystic Fibrosis: A Study Based On European Cystic Fibrosis Society Patient Registry Data. Società Italiana di Statistica Medica ed Epidemiologia Clinica (SISMEC) XIII Congresso - Pavia (Italy). Settembre 2025. Epidemiology, Biostatistics, and Public Health. 

Adamoli , A., Orenti, A.Gambazza, S., Zo, lin, A., Ambrogi, F., De Rose , V., & ECFSPR Steering Group

Clinical Outcomes and Survival Differences in People with Cystic Fibrosis Living in Europe. Epidemiology, Biostatistics, and Public Health.

Orenti, A., Naehrlich, L., Bakkeheim, E., Hatziagorou, E., Kerem, E., & Sermet-Gaudelus, I.

Evaluating The Real-World Effectiveness Of A New Class Of Drugs For Cystic Fibrosis: A Study Based On European Cystic Fibrosis Society Patient Registry Data. Epidemiology, Biostatistics, and Public Health.

 

Adamoli, A., Orenti, A., Gambazza, S., Zolin, A., Ambrogi, F., De Rose, V., & ECFSPR Steering Group.

WS02.05 Assessment of respiratory infection following initiation of elexacaftor/tezacaftor/ivacaftor using the European Cystic Fibrosis Society patient registry. Journal of Cystic Fibrosis, 23, S4.

Pollak, M., Gambazza, S., Orenti, A., Rens, J. van, Rose, V. de, & Zahav, M. M. (2024).

P102 Methicillin-resistant Staphylococcus aureus and pulmonary outcome in people with cystic fibrosis: a European Cystic Fibrosis Patient Registry data analysis. Journal of Cystic Fibrosis, 23, S116.

Mei-Zahav, M., Dotan, M., Annicchiarico, L., Orenti, A., & Prais, D. (2024).

WS02.03 Disease burden in people with cystic fibrosis according to CFTR genotype and eligibility to CFTR modulator therapy: a ECFS Patient Registry analysis. Journal of Cystic Fibrosis, 23, S3–S4.

Tomarelli, I., Orenti, A., Burgel, P.-R., Gramegna, A., & Blasi, F. (2024).

EPS6.03 Factors associated with more frequent and severe pulmonary exacerbations in patients with cystic fibrosis: data from the ECFS Patient Registry. Journal of Cystic Fibrosis, 23, S50.

de Rose, V., Orenti, A., Adamoli, A., van Rens, J., Pollak, M., & Mei Zahav, M. (2024).

EPS6.01 Improved outcome in the adult cystic fibrosis population in Europe from 2012 to 2022: analysis of the European Cystic Fibrosis Society Patient Registry. Journal of Cystic Fibrosis, 23, S50.

Orenti, A., Hatziagorou, E., Kerem, E., de Boeck, C., & Burgel, P.-R. (2024).

714 Association between change in Pseudomonas aeruginosa infection and clinical outcomes after elexacaftor/tezacaftor/ivacaftor treatment: data from the European Cystic Fibrosis Society Patient Registry. Journal of Cystic Fibrosis, 23, S404.

Pollak, M., Gambazza, S., Orenti, A., van Rens, J., de Rose, V., Prais, D., Kerem, E., & Mei-Zahav, M. (2024).

WS02.02 Worldwide prevalence of F508del and rare CFTR variants responsive to elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis, 23, S3.

Burgel, P.-R., Orenti, A., Cromwell, L., & Stephenson, A. (2024).

WS02.01 Health inequality in Europe in cystic fibrosis people. Journal of Cystic Fibrosis, 23, S3.

Sermet-Gaudelus, I., Orenti, A. L., Hatziagorou, E., Bakkeheim, E., Kerem, E., & Nearhrlich, L. (2024).

P115 A retrospective analysis of the ECFSPR to characterise the pulmonary phenotype and use of intravenous antibiotics in people with cystic fibrosis harbouring bi-allelic CFTR class 1 mutations. Journal of Cystic Fibrosis, 23, S120–S121.

Orenti, A., Mountford, W. K., Davies, J. C., Polineni, D., Adamoli, A., Bakkeheim, E., Isabelle, I., Mall, M. A., Alves, C. P., Seibold, W., Sigmund, R., & Carr, S. B. (2024).

465 Bridging the gap for health inequality in lowincome countries : lessons from cystic fibrosis during the last decade in Europe. Journal of Cystic Fibrosis, 23, S252.

Sermet-Gaudelus, I., Orenti, A., Hatziagorou, E., Bakkeheim, E., Kerem, E., & Naehrlich, L. (2024).

P120 Utilisation of multiple breath washout in Europe differs substantially between age groups and countries. Journal of Cystic Fibrosis, 23, S122.

Naehrlich, L., Zolin, A., Lindblad, A., & Gkolia, P. (2024).

WS03.01 Differences in disease severity among different residual function mutations: data from the ECFS Patient Registry. Journal of Cystic Fibrosis, 22, S5–S6.

Mei-Zahav, M., Orenti, A., Jung, A., van Rens, J., & Kerem, E. (2023).

616 It takes a village: cystic fibrosis research beyond borders. Journal of Cystic Fibrosis, 22, S329.

Cheng, S., Naito, Y., Charman, S., Gutierrez, H., Jung, A., van Rens, J., Orenti, A., Karadag, B., Elbert, A., & Stephenson, A. (2023).

WS08.01 The changing epidemiology of cystic fibrosis in Europe from 2010 to 2019: data from the European Cystic Fibrosis Society Patient Registry. Journal of Cystic Fibrosis, 21, S15.

Hatziagorou, E., Orenti, A., Naehrlich, L., Rossi, M., Mei-Zahav, M., van Rens, J., Zolin, A., Carr, S., Burgel, P.-R., Daneau, G., Storms, V., Lammertyn, E., Lindblad, A., Macek, M., & Jung, A. (2022).

WS01.02 Trends and outcomes of long-term inhaled antimicrobial treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection: an ECFSPR data analysis. Journal of Cystic Fibrosis, 21, S1–S2.

Shteinberg, M., Orenti, A., Mei-Zahav, M., Boracchi, P., & Lindblad, A. (2022).

P178 Lung transplantation and mortality in patients with cystic fibrosis under oxygen therapy. Journal of Cystic Fibrosis, 19, S106.

Gambazza, S., Ambrogi, F., Zolin, A., & Orenti, A. (2020).

WS13.4 Distribution of cystic fibrosis patients not eligible to studied CFTR modulators in Europe. Journal of Cystic Fibrosis, 19, S22.

Zolin, A., Orenti, A., Barbier, A., van Rens, J., & Naehrlich, L. (2020).

S23.2 Epidemiology of European adults with cystic fibrosis. Journal of Cystic Fibrosis, 19, S35.

Zolin, A., Naehrlich, L., Fox, A., Krasynk, M., Orenti, A., & van Rens, J. (2020).

P080 The European Cystic Fibrosis Society Patient Registry (ECFSPR) data validation programme: accuracy and consistency of data. Journal of Cystic Fibrosis, 18, S80.

Naehrlich, L., Fox, A., Krasynk, M., Orenti, A., Zolin, A., & van Rens, J. (2019).